Mark Moss, MD
Allergy · Madison, WINPI 1093781163
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,795 of the $16,156 with a category attached, or 85.4%. Regeneron Healthcare Solutions, Inc. accounts for 66.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $13,758 and has fallen 99.3% since, to $99 in 2024.
Across 24 payments — averaging $673.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$11K
- Optinose US, Inc.$4K
- Biocryst Pharmaceuticals, Inc.$1K
- Imperative Care, Inc$125
- AstraZeneca$99
Across 121 payments — averaging $7768.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$312K
- Regeneron$307K
- Sanofi US Services Inc.$109K
- Teva Pharmaceuticals USA, Inc.$81K
- GSK$70K
- Novartis$54K
- plus $7K from 2 others
What the payments were for
- Consulting fees$13,79585%
- Travel & lodging$1,81511%
- Food & beverage$5473%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $10,743 |
| Optinose US, Inc. | 8 | $3,814 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,375 |
| Imperative Care, Inc | 1 | $125 |
| AstraZeneca | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$10,315
- Xhance$3,667
- ZOOM REPERFUSION CATHETER$125
- ZOOM 88-T LARGE DISTAL PLATFORM$125
How this compares
Too few allergy providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 35 | $126,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,205 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,892 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $6,520 |
| OdactraMite,d.Farinae-D.Pteronyssinus | 11 | $3,632 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $3,469 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,676 |
| Fluticasone Propionate | 46 | $1,166 |
| Montelukast Sodium | 69 | $923 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $720 |
| Azelastine Hcl | 33 | $709 |
| Famotidine | 12 | $301 |
| Prednisone | 17 | $69 |
| Ciprofloxacin Hcl | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other allergy in Madison
- Ravi ViswanathanMadison$4K
- Courtney GaberinoMadison$1K
- Helen SandersonMadison$762
- Ivana SurjancevMadison$34
- Mark BiagtanMadison$19
- David EdmondsonWausau$207K
- Gary StevenGreenfield$153K
- Pedro BandaMilwaukee$149
- Martin LobelMilwaukee$123
- Michael GanzRacine$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.